Modified cisplatin/interferon [alpha]-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma

BACKGROUND The purpose of this study was to evaluate the factors associated with response rate, resectability, and survival after cisplatin/interferon [alpha]-2b/doxorubicin/5-fluorouracil (PIAF) combination therapy in patients with initially unresectable hepatocellular carcinoma. METHODS The study...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer 2013-09, Vol.119 (18), p.3334-3342
Hauptverfasser:	Kaseb, Ahmed O, Shindoh, Junichi, Patt, Yehuda Z, Roses, Robert E, Zimmitti, Giuseppe, Lozano, Richard D, Hassan, Manal M, Hassabo, Hesham M, Curley, Steven A, Aloia, Thomas A, Abbruzzese, James L, Vauthey, Jean-Nicolas
Format:	Artikel
Sprache:	eng
Schlagworte:	5-Fluorouracil Hepatitis B virus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!